{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:31:47Z","timestamp":1778344307638,"version":"3.51.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1D1A1B07045202"],"award-info":[{"award-number":["2018R1D1A1B07045202"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2012-0035"],"award-info":[{"award-number":["6-2012-0035"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>We aimed to determine the significance of cytoplasmic antinuclear antibody (ANA) patterns using computer-aided immunofluorescence microscopy in patients with autoimmune liver diseases (AILD). ANA staining pattern was identified by treating cultured human epithelial type 2 (HEp-2) cells with the sera of the patients. Medical records of patients with suspected AILD who had positive cytoplasmic ANA patterns between February 2017 and November 2019 were retrospectively reviewed for clinical, laboratory, and immunological data. Cytoplasmic ANA patterns of AILD and non-AILD groups were compared. Further subgroup analysis of patients with AILD who had reticular or speckled cytoplasmic ANA patterns was conducted. We found that among the 196 patients with positive cytoplasmic ANA patterns, 113 (57.6%) were diagnosed with AILD. The percentage of reticular cytoplasmic pattern was higher in the AILD group than that in the non-AILD group (64.0% vs. 21.9%, p &lt; 0.001). Furthermore, patients with AILD who exhibited a reticular ANA pattern demonstrated a higher positive rate for anti-mitochondrial antibodies (66.7% vs. 2.6%, p &lt; 0.001) than those who exhibited the speckled ANA pattern. Moreover, AILD patients with the reticular ANA pattern displayed a lower positive rate for anti-smooth muscle antibodies (0% vs. 45%, p &lt; 0.001) and nuclear ANA pattern (73.2% vs. 97.5%, p = 0.003) than those with the speckled ANA pattern. Therefore, cytoplasmic ANA patterns could be used to guide AILD characterization in suspected AILD cases, especially as the reticular ANA pattern is strongly associated with AILD. Thus, it is important to check cytoplasmic ANA patterns for AILD evaluation, even when nuclear ANA patterns are negative.<\/jats:p>","DOI":"10.1371\/journal.pone.0244950","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:29:09Z","timestamp":1610054949000},"page":"e0244950","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease"],"prefix":"10.1371","volume":"16","author":[{"given":"Hyun Jin","family":"Cha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy Eunju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-7704","authenticated-orcid":true,"given":"Jason Jungsik","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"4","key":"pone.0244950.ref001","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000444471","article-title":"The Pathogenesis of Autoimmune Liver Disease","volume":"34","author":"K Arndtz","year":"2016","journal-title":"Dig Dis"},{"issue":"1","key":"pone.0244950.ref002","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"G Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"pone.0244950.ref003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"AF Gulamhusein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"pone.0244950.ref004","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrgastro.2010.155","article-title":"Primary sclerosing cholangitis: overview and update","volume":"7","author":"F Mendes","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"pone.0244950.ref005","first-page":"OD07","article-title":"Autoimmune Hepatitis\u2014Primary Biliary Cirrhosis Overlap Syndrome","volume":"11","author":"I Bairy","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"1","key":"pone.0244950.ref006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"N Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"pone.0244950.ref007","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance","volume":"9","author":"M Sebode","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0244950.ref008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2010\/431913","article-title":"Autoantibodies and liver disease: uses and abuses","volume":"24","author":"MV Zeman","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"24","key":"pone.0244950.ref009","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"JR Hov","year":"2008","journal-title":"World J Gastroenterol"},{"key":"pone.0244950.ref010","first-page":"412","article-title":"Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014\u20132015","volume":"6","author":"EK Chan","year":"2015","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0244950.ref011","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"J Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0244950.ref012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-1-2","article-title":"Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease","volume":"1","author":"K Zachou","year":"2004","journal-title":"J Autoimmune Dis"},{"issue":"10","key":"pone.0244950.ref013","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3748\/wjg.v20.i10.2606","article-title":"Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance","volume":"20","author":"S Yamagiwa","year":"2014","journal-title":"World J Gastroenterol"},{"key":"pone.0244950.ref014","doi-asserted-by":"crossref","first-page":"315179","DOI":"10.1155\/2014\/315179","article-title":"Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"2014","author":"M Mahler","year":"2014","journal-title":"J Immunol Res"},{"key":"pone.0244950.ref015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"EM Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"pone.0244950.ref016","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"KD Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"pone.0244950.ref017","first-page":"326","article-title":"The overlap syndromes of autoimmune hepatitis","volume":"58","author":"AJ Czaja","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"7","key":"pone.0244950.ref018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1155\/2013\/198070","article-title":"Diagnosis and management of the overlap syndromes of autoimmune hepatitis","volume":"27","author":"AJ Czaja","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"pone.0244950.ref019","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"R Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"pone.0244950.ref020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0029-1233533","article-title":"Autoantibodies and their antigens in autoimmune hepatitis","volume":"29","author":"DP Bogdanos","year":"2009","journal-title":"Semin Liver Dis"},{"key":"pone.0244950.ref021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejim.2017.10.006","article-title":"Serology in autoimmune hepatitis: A clinical-practice approach","volume":"48","author":"B Terziroli Beretta-Piccoli","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"21","key":"pone.0244950.ref022","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3748\/wjg.14.3374","article-title":"Autoimmune liver serology: current diagnostic and clinical challenges","volume":"14","author":"DP Bogdanos","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pone.0244950.ref023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0244950.ref024","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","article-title":"Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases","volume":"19","author":"M Satoh","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"3","key":"pone.0244950.ref025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaut.2010.06.019","article-title":"Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells","volume":"35","author":"AS Wiik","year":"2010","journal-title":"J Autoimmun"},{"issue":"Suppl 2","key":"pone.0244950.ref026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000440747","article-title":"Role of Histopathology in Autoimmune Hepatitis","volume":"33","author":"DG Tiniakos","year":"2015","journal-title":"Dig Dis"},{"issue":"6","key":"pone.0244950.ref027","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.semarthrit.2017.10.004","article-title":"Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry","volume":"47","author":"B Mar\u00ed-Alfonso","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"pone.0244950.ref028","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/ard.2002.001826","article-title":"Hepatic manifestations of autoimmune rheumatic diseases","volume":"63","author":"S Abraham","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"pone.0244950.ref029","article-title":"Development of anti-centromere antibody-positive autoimmune hepatitis after childbirth","author":"M Saito","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"pone.0244950.ref030","doi-asserted-by":"crossref","first-page":"742080","DOI":"10.1155\/2013\/742080","article-title":"Autoimmune hepatitis with anti-centromere antibodies","volume":"2013","author":"M Lodh","year":"2013","journal-title":"Case Reports Immunol"},{"issue":"6","key":"pone.0244950.ref031","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinre.2013.04.005","article-title":"Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis","volume":"37","author":"R Liberal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:30:32Z","timestamp":1610055032000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244950"}},"subtitle":[],"editor":[{"given":"Gianfranco D.","family":"Alpini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244950","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}